8-K: Revelation Biosciences Reports 2025 Financials, Gemini Progress

Revelation Biosciences, Inc. announced its financial results for the three and twelve months ended December 31, 2025, highlighting positive clinical study results for its Gemini program.

Summary

• Cash and cash equivalents increased to $10.7 million as of December 31, 2025, up from $6.5 million as of December 31, 2024.
• Net cash used for operating activities significantly decreased to $8.3 million for the twelve months ended December 31, 2025, compared to $18.3 million for the same period in 2024.
• Net loss for the three months ended December 31, 2025, was $2.5 million, or $(1.65) basic and diluted net loss per share, an improvement from $1.7 million, or $(59.76) per share, for the same period in 2024.
• Net loss for the year ended December 31, 2025, was $8.9 million, or $(23.95) basic and diluted net loss per share, a substantial improvement from $15.0 million, or $(1,052.16) per share, for the year ended December 31, 2024.
• The company announced positive results from its PRIME Clinical Study in late-stage chronic kidney disease patients.
• An agreement was reached with the FDA on a single adaptive Phase 2/3 study for approval of Gemini for the treatment of acute kidney injury.
• Revelation Biosciences received net proceeds of $6.7 million from a warrant inducement in January 2026.
• Based on current operating plans, current cash and cash equivalents are sufficient to fund operations into the first quarter of 2027.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report given the significant reduction in net loss and cash burn, coupled with crucial clinical and regulatory advancements for its lead program, Gemini, which extends its cash runway.

Positives

• Cash and cash equivalents increased to $10.7 million by December 31, 2025, from $6.5 million in 2024.
• Net cash used for operating activities significantly decreased to $8.3 million in 2025 from $18.3 million in 2024.
• Net loss for the year decreased to $8.9 million in 2025 from $15.0 million in 2024.
• Net loss per share significantly improved to $(23.95) in 2025 from $(1,052.16) in 2024.
• Positive results were announced from the PRIME Clinical Study in late-stage chronic kidney disease patients.
• An agreement was reached with the FDA on a single adaptive Phase 2/3 study for Gemini for acute kidney injury.
• The company received $6.7 million in net proceeds from a warrant inducement in January 2026.
• Current cash is projected to fund operations into the first quarter of 2027, extending the cash runway.

Negatives

• The company continues to report a net loss, with $8.9 million for the year ended December 31, 2025.
• Research and development expenses increased to $4.06 million in 2025 from $3.55 million in 2024.
• General and administrative expenses increased to $5.01 million in 2025 from $4.43 million in 2024.

Risks

• The ability of Revelation to meet its financial and strategic goals, due to, among other things, competition.
• The ability of Revelation to grow and manage growth profitability and retain its key employees.
• The possibility that Revelation may be adversely affected by other economic, business, and/or competitive factors.
• Risks relating to the successful development of Revelation's product candidates.
• The ability to successfully complete planned clinical studies of its product candidates.
• The risk that the company may not fully enroll its clinical studies or enrollment will take longer than expected.
• Risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from clinical studies.
• Changes in applicable laws or regulations.
• Uncertainty regarding the expected initiation of clinical studies, the timing of clinical data, and the outcome of clinical data.
• The risk that the results of clinical studies may not be positive or replicable.
• Uncertainty regarding the timing, costs, conduct, and outcome of other clinical studies.
• The anticipated treatment of future clinical data by the FDA, the EMA, or other regulatory authorities, including whether such data will be sufficient for approval.
• The success of future development activities for its product candidates and potential indications for which product candidates may be developed.
• The ability of Revelation to maintain the listing of its securities on NASDAQ.
• The expected duration over which Revelation's balances will fund its operations.

Future Outlook

Revelation Biosciences anticipates building on the momentum of 2025 to expeditiously bring Gemini to patients in need and add to shareholder value in 2026. The company projects its current cash and cash equivalents to be sufficient to fund operations into the first quarter of 2027.

Management Comments

• "2025 was a positive year for Revelation with significant advancement of the Gemini program."
• "We look forward to building on this momentum in 2026 to expeditiously bring Gemini to patients in need and adding to shareholder value."

Industry Context

StockSavvy.ai notes that the positive clinical results for Gemini in chronic kidney disease and the FDA agreement for a Phase 2/3 study in acute kidney injury position Revelation Biosciences favorably within the competitive landscape of renal disease therapeutics. The focus on rebalancing inflammation via TLR4 agonism represents a distinct approach in a field with significant unmet medical needs, potentially differentiating Gemini from other pipeline candidates targeting kidney dysfunction.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value due to positive clinical results, FDA agreement, and extended cash runway. Reduced net loss and cash burn are also positive.
• Patients: Gemini program advancements offer potential new treatments for acute kidney injury, chronic kidney disease, severe burn, and post-surgical infection.
• Employees: Continued operations and program advancement suggest stability and ongoing work.
• Creditors: Improved cash position and reduced cash burn may enhance creditworthiness.

Next Steps

• Present clinical data on Gemini for AKI and CKD at the International Conference on Advances in Critical Care Nephrology (March 29 April 1, 2026).
• Expeditiously bring Gemini to patients in need in 2026.
• Continue building on momentum in 2026 to add shareholder value.
• Advance the single adaptive Phase 2/3 study for Gemini for acute kidney injury.

Key Dates

Recommendation

The significant reduction in net loss and cash burn, combined with positive clinical trial results for the PRIME study and an FDA agreement for a Phase 2/3 study for Gemini, indicates strong operational and clinical progress. The extended cash runway into Q1 2027 provides financial stability. These developments suggest a positive trajectory for the company's lead asset and could lead to substantial value creation, making it an attractive investment for long-term growth.

Keywords

Revelation Biosciences, REVB, Gemini, acute kidney injury, chronic kidney disease, TLR4 agonist, clinical-stage, biotechnology, life sciences, inflammation, financial results, SEC filing, PRIME study, FDA agreement, warrant inducement